Azelaic Acid: Does It Actually Work?
Azelaic acid treats acne, helps some forms of pigmentation, and has a surprisingly decent evidence base. But how much of the skincare hype does the research actually support?
Disclosure
Nothing here is sponsored and we earn nothing from anything mentioned. If that ever changes, this box will say so before you read a word of the article.
Evidence at a glance
- Acne
- B Good evidence against vehicle. The main review was run by a company that sells it.
- Melasma
- B Better than vehicle. The hydroquinone comparison used 2%, not the standard 4%.
- PIH
- B 15% azelaic acid has clinical evidence for improving acne-associated post-inflammatory hyperpigmentation.
- Anti-ageing
- D Sounds plausible. Clinical evidence? Surprisingly little.
- Tolerability
- B Generally well tolerated, but burning, stinging and dryness can still happen.
Azelaic acid is having a moment. It treats acne, helps with rosacea, fades some kinds of pigmentation, and gets credited with anti-inflammatory, antimicrobial and even anti-ageing powers — at which point you start to wonder if it also does your taxes.
The real research is narrower than the marketing, and more interesting for it. There's good evidence for acne, reasonably good evidence for rosacea and melasma, and encouraging early evidence for post-inflammatory hyperpigmentation (PIH). Past that, the evidence thins out fast. Here's what's actually behind each claim.
Acne and melasma: the strongest claims
Evidence grade: B — Moderate
This part isn't controversial. Trials have repeatedly found azelaic acid beats an inactive vehicle for acne, and a 2023 systematic review pooled 16 supporting trials. Its anti-inflammatory and antimicrobial activity, plus an effect on the abnormal skin-shedding that clogs pores, are plausible reasons why. One thing worth flagging once rather than burying: every author on that review works for the Dermatica Institute of Clinical Excellence, which sells azelaic acid. Three of the claims on this page trace back to it.
"Works" isn't the same as "works best": head-to-head trials against other acne treatments are mixed, sometimes favouring azelaic acid, sometimes not. Worth knowing before a marketing team gets hold of that distinction.
The same review found seven trials backing azelaic acid for melasma, beating vehicle and comprehensively beating hydroquinone 2%. But against 4% hydroquinone, the concentration doctors actually reach for, the same review found no significant difference. Beating the weaker version while tying the real one is a smaller win than "beats hydroquinone" sounds like. A separate meta-analysis of six trials in 673 people, published in Cureus (a journal with noticeably lighter peer review than the others cited here), found azelaic acid ahead of hydroquinone on one pigmentation score but tied on most others. Put together: a legitimate melasma treatment, on par with the standard-strength alternative rather than a clear upgrade on it.
Pigmentation: real, but not one thing
Evidence grade: B — Moderate
A 2024 randomised, placebo-controlled trial of 15% azelaic acid gel in 60 people with acne found it significantly reduced melanin in PIH lesions by week 12. An older trial in Fitzpatrick IV–VI skin found 20% azelaic acid beat vehicle for facial hyperpigmentation over 24 weeks, on both investigator and instrumental measurement. That's genuinely useful, since pigmentation treatments don't always transfer cleanly across skin tones. A further, older trial tested it alongside glycolic acid rather than alone, so it's supporting context rather than proof about azelaic acid by itself.
Worth knowing before you file this under "gentle": burning and stinging showed up more often with azelaic acid than vehicle in that darker-skin trial. Generally well tolerated is accurate. Immune to irritating anyone is not.
One caveat on scope: melasma, PIH and an ordinary sun spot are three different things wearing the same "dark patch" costume. Evidence for one doesn't automatically transfer to the others, even though azelaic acid happens to have real evidence for more than one of them.
What the evidence doesn't support
Evidence grade: D — Insufficient
Two claims worth deflating. First: more isn't obviously better. The strongest pigmentation data uses 20% azelaic acid, the PIH data uses 15%. That's not a clean staircase where higher numbers mean better results, and a brand's 10% product isn't entitled to borrow a 20% trial's results just because it's "the same ingredient." Concentration and formulation both matter, and neither transfers automatically.
Second: anti-ageing. That same 2023 review went looking for randomised trials of azelaic acid against skin ageing and found none at all. That's a null result from the one group with every commercial incentive to find something, which makes it more credible, not less. It doesn't prove azelaic acid does nothing for wrinkles. It just means nobody has actually checked. Real acne benefit plus real pigmentation benefit plus antioxidant properties don't automatically add up to a proven anti-ageing treatment. Skincare ingredients don't get to collect benefits like Pokémon.
The verdict
Yes, it works. For acne, there's good trial support. For melasma and rosacea, the evidence is meaningful if not conclusive, particularly at 15–20%. And for acne-related PIH, the data is early but genuinely promising. For general anti-ageing, or for "brightening" whatever dark patch happens to be bothering you, the evidence isn't there yet.
If you're using it for pigmentation, think weeks to months, not three Instagram reels and a miracle. And the useful question when comparing it to another active isn't "which one's better." It's "better for what." Not a miracle ingredient. Not snake oil. Just an ingredient that actually has some receipts.
This is general education, not medical advice. Nothing here accounts for your history, your medication or your skin, and none of it replaces assessment by a qualified clinician. Where we describe what research found, that is a description of a study — not a promise about you.
Revision history
- Added a disclosure that the 2023 systematic review underpinning several of this article's claims is authored entirely by staff of the Dermatica Institute of Clinical Excellence, which sells azelaic acid products. The findings themselves are unchanged, but the funding context is now attached throughout rather than mentioned once in passing.
- Rewritten for length. The article repeated the same points across eight separate claim sections, and it's now four. Every citation, the funding disclosure, and all the caveats (the 2%-vs-4% hydroquinone comparison, the Cureus peer-review note, the concentration/formulation point, the null anti-ageing finding) are still here, just said once each instead of several times.
References
- King S, Campbell J, Rowe R, Daly ML, Moncrieff G, Maybury C A systematic review to evaluate the efficacy of azelaic acid in the management of acne, rosacea, melasma and skin aging. Journal of cosmetic dermatology, 2023.PubMed 37550898
- Shucheng H, Zhou X, Du D, Li J, Yu C, Jiang X Effects of 15% Azelaic Acid Gel in the Management of Post-Inflammatory Erythema and Post-Inflammatory Hyperpigmentation in Acne Vulgaris. Dermatology and therapy, 2024.PubMed 38734843
- Lowe NJ, Rizk D, Grimes P, Billips M, Pincus S Azelaic acid 20% cream in the treatment of facial hyperpigmentation in darker-skinned patients. Clinical therapeutics, 1998.PubMed 9829446
- Kakita LS, Lowe NJ Azelaic acid and glycolic acid combination therapy for facial hyperpigmentation in darker-skinned patients: a clinical comparison with hydroquinone. Clinical therapeutics, 1998.PubMed 9829447
- Albzea W, AlRashidi R, Alkandari D, Sadan M, Alkandari A, Alkanderi JJ, AlHajri MT, Almutairi SN, Alenzi A, Alanazi S, Al-Qurashi S, Alhajaji R, Al Shami A Azelaic Acid Versus Hydroquinone for Managing Patients With Melasma: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus, 2023.PubMed 37457606DOI 10.7759/cureus.41796
- Sarkar R, Bhalla M, Kanwar AJ A comparative study of 20% azelaic acid cream monotherapy versus a sequential therapy in the treatment of melasma in dark-skinned patients. Dermatology (Basel, Switzerland), 2002.PubMed 12399672
Related condition hubs
AcneRosacea & facial rednessPigmentation & melasmaPost-inflammatory hyperpigmentation (PIH)Perioral dermatitis
Your turn
Did this hold up? Tell us honestly — especially if it didn’t.